JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 31, 2007; DOI: 10.1124/jpet.106.118810


0022-3565/07/3212-544-552$20.00
JPET 321:544-552, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.118810v1
321/2/544    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, D.
Right arrow Articles by Sadee, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, D.
Right arrow Articles by Sadee, W.

CELLULAR AND MOLECULAR

Different Effects of Opioid Antagonists on µ-, {delta}-, and {kappa}-Opioid Receptors with and without Agonist Pretreatment

Danxin Wang, Xiaochun Sun, and Wolfgang Sadee

Department of Pharmacology, School of Medicine and Public Health, The Ohio State University, Columbus, Ohio

Opioid receptors display basal signaling (constitutive, agonist-independent activity), which seems to be regulated by agonist exposure. Whereas agonist pretreatment desensitizes receptors to subsequent agonist stimulation, basal signaling of µ-opioid receptor (MOR) was shown to increase. Moreover, agonist pretreatment converts the neutral antagonists naloxone and naltrexone into inverse agonists, suppressing basal signaling, whereas analogs with reduced C6-position, e.g., 6beta-naltrexol, remain neutral antagonists at MOR under any condition. This study compares the regulation of basal signaling of MOR, {delta}-(DOR), and {kappa}-(KOR) opioid receptors after pretreatment with morphine or receptor-selective agonists, in transfected human embryonic kidney 293 cell membranes. Moreover, naloxone, naltrexone, and related antagonists were compared for binding potency and effect on basal and agonist-stimulated receptor signaling, measuring guanosine 5'-O-(3-[35S]thio)triphosphate binding. The results demonstrate basal activity for each opioid receptor, which is modulated by pretreatment with agonists. Even closely related opioid antagonists display distinct patterns of neutral and inverse effects before and after agonist pretreatment, including distinct efficacies between naloxone and naltrexone at agonist-pretreated DOR and KOR. Pretreatment with different agonists has varying effects on inverse and neutral activities of some analogs tested. These results demonstrate that antagonist efficacy is context-dependent, possibly accounting for paradoxical pharmacological effects. Activity profiles at the three opioid receptors under different conditions could lead to antagonists with optimal clinical properties in treatment of addiction and adverse opioid effects.


Received December 19, 2006; accepted January 29, 2007.

Address correspondence to: Dr. Wolfgang Sadée, Department of Pharmacology, Graves Hall 5072, College of Medicine, The Ohio State University, 333 West 10th Ave., Columbus, OH 43210. E-mail: wolfgang.sadee{at}osumc.edu




This article has been cited by other articles:


Home page
FASEB J.Home page
V. Vukojevic, Y. Ming, C. D'Addario, M. Hansen, U. Langel, R. Schulz, B. Johansson, R. Rigler, and L. Terenius
{micro}-Opioid receptor activation in live cells
FASEB J, October 1, 2008; 22(10): 3537 - 3548.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Sirohi, P. Kumar, and B. C. Yoburn
{micro}-Opioid Receptor Up-Regulation and Functional Supersensitivity Are Independent of Antagonist Efficacy
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 701 - 707.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.